Display Technologies for the Selection of Monoclonal Antibodies for Clinical Use

1. Introduction

The sale of therapeutic monoclonal antibodies (mAbs) is increasing yearly in relation to other class of biological products [1], and pharmaceutical/biotechnological companies are pursuing all opportunities to develop this product. Therapeutic mAbs are indicated to diverse clinical conditions such as treatment of cancers, immune-mediated disorders and infectious diseases, among others. Every year, new mAbs are approved while a crescent number of other mAbs advance to the next phase of clinical study [2].

Generation of mAbs started with the discovery of the hybridoma technology by Köhler and Milstein [3] in 1975. The fusion of B cells from immunized animals with myeloma cells originated hybrid cells producing unlimited quantities of antibodies with unique specificities. The potential of this technique for clinical and diagnostic use became evident with the approval of the first therapeutic mAb 10 years later, Orthoclone OKT3 targeting the CD3 receptor present in T lymphocytes to control renal transplantation rejection [4]. The clinical success conducted immediately to the development of other mAbs derived from this technology. However, due to the non-conforming sequence of murine mAbs, the generation of an immune response in humans was observed and the use of higher and multiple doses for prolonged time was not possible. Murine mAbs can induce immunogenicity, human anti-mouse antibodies (HAMA, including human anti-idiotype antibodies) affecting the safety and therapeutic efficacy [5]. The evaluation of mAb immunogenicity is crucial during clinical trials and it is recommended by regulatory agencies.

With advances in the understanding of antibody structure and in molecular biology techniques, the field of antibody engineering emerged with objective to change antibody properties by altering its primary sequence. Antibody humanization techniques use antibody engineering approaches to produce antibodies with less immunogenicity and preservation of affinity and specificity of the parental antibody of non-human origin [6]. The first humanization technique led to the combination of variable region domains of a murine antibody with human constant region domains resulting in chimeric antibodies with 70% of human content [7]. Chimeric antibodies maintained the specificity of parental murine antibody and demonstrated decreased immunogenicity, however, they generated human anti-chimeric antibodies (HACA) in approximately 40% of patients [5]. Efforts to obtain mAbs with a minimum of immunogenicity resulted in the development of a technique where sequences responsible for the antibody specificity to the antigen called complementarity-determining regions (CDRs) were transplanted to human framework sequences. This technique was designated CDR grafting and generated humanized antibodies [8, 9, 10]. However, it was observed that most of the antibodies obtained by CDR grafting did not preserve the affinity of the parental murine antibody. This fact is due to the influence of the human framework on the structure of the transplanted mouse CDRs [11, 12]. Through 3-dimensional modeling, key residues were identified in the murine framework sequences that interacted with CDRs and the antigen representing the integrity of the antigen-binding site. In a maneuver of back mutating the identified critical framework residues to the mouse framework sequence, antibodies with affinities close to the parental murine antibody were obtained. Using this approach Zenapax^® (daclizumab) was approved by FDA in 1997 for therapeutic use for the prevention of renal transplantation rejection [13]. Soon the antibody humanization technique became viable for the clinical application of mAbs of non-human origin. In relation to immunogenicity, approximately 9% of humanized antibodies induced human anti-humanized antibodies (HAHA) in different clinical trials [5]. A less frequent humanization technique aiming to retain the original antibody affinity by altering only the mouse surface-exposed residues of the framework (veneering) was used with success for an anti-NaPi2b oncologic antibody where the humanized version (Rebmab200) demonstrated a slightly improved affinity in relation to the murine version (MX35) [14, 15].

Concomitant to the utilization of antibody humanization techniques started the development of in vitro display technologies and the exploration of the molecular diversity of the antibody genes present in a determined library. The first technology available was phage display by presenting exogenous peptides on filamentous bacteriophage (phage) surfaces [16]. The peptide sequences were fused to the amino-terminus of the p3 protein of phages and the fusion protein was expressed on the phage surface, further purified by affinity through the binding to a specific antibody. Selected phages were amplified in bacteria. Then, a biopanning process, a classical cyclic procedure to select phage clones presenting peptides by affinity binding was described [17]. The occurrence of the phage display technology to select mAbs depended on the development of two techniques. Firstly, the expression of functional antibody fragments (scFv and Fab fragment) in the periplasm of Escherichia coli was reported [18, 19]. The second technique to mention is the PCR for amplification of antibody genes (heavy and light chains) from hybridomas, a pool of prokaryotic and eukaryotic cells transfected with antibody genes, human peripheral blood cells or tissues rich in B cells [20, 21, 22]. The amplification of human immunoglobulin genes directly from immune or naïve human materials opened the possibility to select human antibodies from these sources, either for diagnostic or clinical purposes. In phage display technology, amplified antibody genes are cloned into appropriate phage display vectors to construct the library. Antibody fragments present in the library are expressed on the phage surface and then are submitted to biopanning to select phages by the binding to a specific peptide epitope or antigen. After some cycles of biopanning, the phages encoding the antibody fragments are analyzed individually to select specific clones. Soluble antibody fragments are expressed allowing the characterization of the antibodies and isolation of lead clones [23, 24]. Using phage display technology, six human mAbs were approved for therapeutic use and other candidates are in advanced phases of clinical studies [25]. Other in vitro display technologies were developed such as yeast display, ribosome display, bacterial display, mRNA display, mammalian cell surface display and DNA display and, although mAbs with therapeutic potential were obtained by using these other in vitro display technologies, no one reached the clinical approval so far.

In the present chapter, we describe discovery technologies to select human therapeutic mAbs.

2. Display technologies to obtain recombinant monoclonal antibodies

In vitro display technologies such as phage display, yeast display, ribosome display, bacterial display, mammalian cell surface display, mRNA display and DNA display represent in vitro selection platforms of specific molecules presented in a determined library. These technologies are used mainly to isolate peptides and antibody fragments in scFv, single domain antibody (sdAb) or Fab fragment formats. These technologies mimic the in vivo process for antibody generation and have four key steps as it occurs in vivo inside the immune system: (1) generation (or cloning) of genotypic diversity; (2) linkage between the genotype and phenotype; (3) application of selective pressure and (4) amplification. This process was initially developed for the collection of recombinant antibody genes from B lymphocytes from immunized mice and naïve or infected humans. The immunoglobulin gene repertoire is cloned into a vector to provide the connection between the genotype and the phenotype of each antibody, and clones are selected through the binding to the specific antigen [26]. The isolated clones are expressed in sufficient amounts to characterize them and to select the best candidate.

The main advantage of the in vitro display technology is the possibility to obtain antibodies to any kind of targets and epitopes because the construction of a naïve or synthetic antibody repertoire is not dependent on an in vivo immune response. Even antibodies against self-antigens, toxic, unstable and non-immunogenic antigens could be isolated by selection from a combinatorial antibody library [25].

Phage display technology is one of the main platforms for generation of human therapeutic antibodies together with transgenic immunized mice, antibody humanization techniques and single B cell expression cloning [26, 27].

2.1. Phage display technology

Phage display technology was the first in vitro display technology developed by presenting an exogenous peptide on the filamentous phage surface [16].

The first antibody combinatorial library was constructed on a λ lytic bacteriophage vector that releases Fab fragments from the periplasm after cell lysis. The screening of Fab fragments was successfully done by transferring the material to nitrocellulose filters followed by binding to radiolabeled antigen [28]. The same methodology was applied for cloning a human antibody library and selection of specific antibodies [29]. The library was constructed from antibody genes of peripheral blood lymphocytes of individuals that had recently received a tetanus toxoid immunization.

Biopanning procedures to select antibody fragments/peptides presented on the phage surface are more efficient for clone screening, since it allows to isolate clones with defined specificity and affinity [17]. Phage display libraries were initially established by the construction of peptide libraries on filamentous phages [30, 31, 32], not lytic to bacteria, and recombinant phages are released at the time they are assembled in the bacterial membrane. The expression of scFvs on the filamentous phage surface was described, allowing antibody selection from the library through binding to the antigen [33, 34]. Fab fragments can be presented on the phage surface and, in this case, one antibody chain is fused to the phage p3 protein and directed in the periplasm and the other antibody chain is secreted directly in the periplasm where the Fab fragment is assembled [35, 36, 37]. The presentation of single domain antibodies (dAbs) on phage surfaces was also reported [38]. The p3 protein is expressed on the external phage surface, presented in five copies, being involved in the bacterial infection through the binding of bacterial F pilus with the N-terminus of p3 protein [39, 40, 41]. The p3 protein vector system is mostly used for the selection of scFv, Fab fragments and single domain antibodies. The advantages are explained in the next section.

2.1.1. Vector systems to display exogenous molecules

Phage was initially used as a cloning vector and exogenous genes were inserted in its genome. This system leads to multiple presentations of exogenous peptides fused with phage p3 or p8 protein, making it difficult to select specific antibodies due to the avidity effect [16]. Antibody fragment genes were fused to the N-terminus of p3 phage protein and it was observed that phages continued to be infective [33, 35]. Phagemid vectors emerged as alternative of direct cloning into the phage genome (Figure 1).

Phagemids are plasmids containing the intergenic region (IR) of filamentous phage. The IR allows replication of the phagemid mediated by helper phage and packing of phagemid single-strand DNA. Phagemid vectors present some advantages in relation to phage genome cloning: double-strand DNA is obtained for library construction, the copy number of the protein presented on the phage surface may be controlled, easy conversion to soluble protein production by insertion of an amber stop codon between recombinant protein and p3 protein [35], and higher stability due to the resistance of exogenous molecules toward deletions [43]. The main protein fusions presented by phagemids are minor p3 or major p8 coat proteins and phagemids contain g3 or g8 genes near to the cloning site of exogenous proteins. Phagemids efficiently express recombinant proteins; however, they do not amplify phages. When bacteria containing phagemids are infected by a helper phage, it is possible to amplify phages since the helper phage synthesizes all phage proteins. Helper phages are filamentous phages with inactive packing signal, replication-deficient origin and generally carry an antibiotic resistance gene. Helper phage superinfection leads to the expression of both wild type protein and fusion protein on the phage surface. During the phage assembly, there is a competition between the two proteins for virion incorporation. Phagemids are preferentially packed by helper phage due to the defective origin of the helper phage [44]. Phage p8 protein is the main surface protein, presenting 2700 copies per phage and has been used to present peptides [45, 46, 47] and antibody fragments [48, 49, 50]. The phage population using p8 fusion protein is multivalent, presenting approximately 900 peptides [46] and 24 Fab fragments [51] per phage particle. In the latter work, it was verified that the avidity effect of multiple copies on the phage surface did not allow selection of antibodies with high affinity. On the other hand, fusion proteins formed by antibody fragments and p3 proteins are presented in 1-3 copies because the expression of the fusion protein can be repressed by an inducible promoter.

Phage incorporates the fusion protein (antibody fragment and p3 protein) in the virion, while the wild-type p3 protein is produced by the helper phage. The presence of wild-type p3 protein is necessary for the bacteria infection. It was observed that when the N-terminal domain of p3 protein binds to bacteria F′ pili, the bacteria cell infected with the phage acquires immunity to the superinfection of other phages such as helper phage [23]. For this reason, the N-terminal domain of the p3 protein was deleted from fusion protein of the first phagemid vector presenting an Fab fragment, pComb3 [36] and other vectors presenting Fab fragments [37, 52].

2.1.2. Antibody library construction

Antibody gene combinatorial libraries with light and heavy chain genes can be constructed from various sources; human peripheral blood is the most used and spleen, lymph nodes and bone marrow are used if possible. The libraries do not represent the repertoire of antibody gene pairs because the heavy and the light chain genes are amplified separately and then paired randomly by PCR or cloning. This feature increases the diversity of the library and consequently the chance to obtain antibody clones with the desired specificity. Therefore, each antibody library represents a unique repertoire.

Basically, there are two kinds of antibody libraries to select recombinant antibodies: the library derived by a source which immune system had not been activated to recognize a specific antigen (naïve), and the immune library derived from donors who received immunization, have been infected or chronically diseased or suffer from cancer [26]. The immune library contains an affinity-matured antibody repertoire and therefore, higher affinity antibodies can be selected in comparison to a naïve library. In the development of human therapeutic antibodies, it is not possible to construct immune libraries to each disease due to ethical issues. Moreover, the construction of a specific library is laborious, high-costing and time-consuming to be considered for each antigen. The option in these cases has been the use of a naïve human library formed by the V, D-J-genes of the IgM repertoire from not intentionally immunized donors. The B cell repertoire can potentially contain also memory cells to previous immunization/infections of donors. In principle, a naïve library can be applied for mAb selection to any kind of antigen, since the library comprises a high variability of immunoglobulin genes and comprises antibody genes from many donors. Some antibodies isolated from a human naïve library presented good specificity to the target and low affinity being necessary to increase it for clinical applications [53]. Naïve human libraries later constructed presented larger sizes and higher affinity clones could be selected. As examples, we can cite Dyax (now Shire) [54], CAT [55, 56], XOMA [57] and HAL [58, 59] naïve human libraries. To increase the variability and size, human semi-synthetic and synthetic libraries [60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73] were constructed based on germline framework sequences, framework sequences of known antibody sequences, consensus framework sequences and human germline VH and VL gene segments. The diversity of antibody sequences was particularly introduced by randomization of CDR sequences, mainly CDR3. A semi-synthetic library was obtained by random mutation of the CDR3 sequence of the heavy chain from a single antibody clone [60] resulting in higher affinity derived clones. An alternative to randomization of CDRs was devised, introducing any codon combination at a specific position to obtain more nature-like antibodies [74] using two strategies: trinucleotide phosphoramidites [66, 68, 70] and Slonomics approaches [71, 72]. HuCAL, HuCAL GOLD and HuCAL PLATINUM libraries are examples of synthetic libraries obtained by trinucleotide phosphoramidites [66, 68, 70] and the Ylanthia library was constructed by the Slonomics method [72].

2.1.3. Antibody selection from library

The scheme of antibody phage display technology is shown in Figure 2. The selection of phages presenting specific antibodies occurs by the specific binding to the antigen by a biopanning process. Only phages expressing antibodies on the surface are amplified and after the biopanning process, the library is enriched with clones presenting moderate or high affinity to the antigen. In principle, only a single round of selection would be sufficient, however, unspecific binding of antibodies presented by phages limits the library enrichment and in practice, two to five rounds of a biopanning process are performed for antibody isolation. Enriched phages obtained at the first round can be amplified in bacteria culture and then submitted to subsequent rounds of biopanning process. Some methodologies were used to isolate phage clones presenting specific antibodies. Phages can be selected by antibody binding to the antigen coated in microplates [36, 53], to antigen-coupled to resins [33], in solution using biotinylated antigens [75], or to antigen present on a cell surface [76]. After antibody phages are bound to the antigen, they are washed and then eluted by soluble antigen [77], acid solution [36] or alkali solution [53].

After antibody clone selection, the candidates are expressed and characterized individually to evaluate their affinity and specificity. Phagemid vectors can display or secrete antibody fragments through incorporation of an amber stop codon between the antibody fragment gene and the p3 protein. Antibody fragments are displayed on the phage surface when the suppressor E. coli strain is transfected and antibodies can be expressed when the non-suppressor E. coli strain is used because the amber codon is read as stop codon in this case [35]. Another option would be the conversion from a phage display vector to an expression vector of a soluble antibody fragment [36] or recloning antibody genes to an expression vector [77].

In general, in the case of naïve or synthetic human antibody libraries, the antibody affinity is proportional to the library size and, in the case of naïve human antibody libraries, the dissociation constant (K_D) was in the 10⁻⁶ to 10⁻⁷ M range for small libraries [53] and in the order of 10⁻⁹ M for larger libraries [55, 57].

2.1.4. Affinity maturation of antibodies

The affinity of antibodies selected by naïve or synthetic phage display antibody libraries is generally adequate for research purposes; however they present low affinity for therapeutic applications. In these cases, selected clones should be submitted to the affinity maturation process [43]. Phage display technology allows the construction of a second antibody library originating from a selected clone, facilitating the selection of human antibodies for therapeutic use. Mutagenesis strategies have been applied to improve antibody affinity [23]. A point mutation library was constructed using error-prone PCR [78] simulating random point mutations generated by natural somatic mutation. This approach was used for anti-progesterone scFv fragments obtained from a naïve antibody library and the antibody affinity increased 30-fold. Other work constructed mutant scFv libraries against digoxigenin with low, moderate and high PCR error rate and showed that the highest antibody affinity improvement was related to higher mutation rates in the positions outside of the CDRs [79]. In addition, introduction of hot spot mutations in antibody germline sequences led to higher affinities of antibodies [80]. This approach presents advantage in relation to previous mutagenesis strategy due to the construction of smaller size libraries allowing parallel screening of multiple mutant libraries.

Mammalian cell surface display of antibody libraries coupled with in vitro somatic hypermutation (SHM) by the action of the activation-induced cytidine deaminase (AID) enzyme emerged as an interesting approach for affinity maturation of human antibodies [81, 82, 83]. In mammalian cell surface display, full-length and glycosylated IgGs are displayed by a transmembrane domain on the cell surface and antibody clones are isolated by screening techniques such as magnetic bead selection followed by in vitro SHM induction of clones which had been selected further by flow cytometry [82]. In vitro SHM has the ability to reproduce the in vivo human antibody maturation in non-B cells and introduces both point mutations and insertion/deletion to the antibody sequence in the region related to antigen contact [83]. One special characteristic of AID is that this enzyme acts preferentially toward germline hotspot motifs (WRCH) present in the antibody DNA sequence, specifically in the variable domains, and promotes point mutations at high rates in amino acid residues which change the antibody binding features [83].

2.1.5. Guided selection technique for antibody humanization

The technique of guided selection has the advantage of allowing selection of a human-nature antibody from a non-human original antibody sequence without the analysis of the antibody structure using in vitro display technology. Two publications demonstrated the viability of this technique using an “in series” process by different approaches [84, 85]. One publication used a rodent heavy chain (MAb32), Fd fragment, as a template and ligated it into a vector containing a human light chain repertoire [84]. A phage repertoire was selected by the antigen and the isolated human light chains were paired to a repertoire of human heavy chains. The selection of phages by the antigen was performed again and a human antibody clone was obtained recognizing the N-terminal region of the mouse antibody’s target and demonstrating a similar affinity constant as the original clone. [84]. Figini et al. constructed a hybrid library combining the light chain of a murine anti-hapten antibody and the human heavy chain repertoire, from which human heavy chain sequences were isolated based on the light-heavy chain pairing ability to combine and bind to the antigen. The selected sequences were paired to the human light chain repertoire to obtain the human antibody [85].

Humira (adalimumab), an anti-TNF-α mAb, was isolated using this technique by an “in parallel” process, and it represents the first fully human antibody and also the first mAb derived by phage display technology approved by FDA in 2002 [86]. This anti-TNF-α mAb was obtained using the rodent antibody sequence (variable domains of heavy and light chains) as a template. Initially, two hybrid libraries were constructed; one formed by pairing the murine heavy chain sequence and a human light chain variable domain repertoire, and the second library was composed of the murine light chain sequence paired to a human heavy chain variable domain repertoire. Both hybrid libraries were selected against TNF-α and the antibody clones were isolated. The human antibody sequences obtained by the screening of each library were combined and the resulting library was reselected against the antigen. A human anti-TNF-α antibody was obtained and, after submitting to CDR mutagenesis, the high affinity D2E7 mAb was isolated with main indications for rheumatoid arthritis and Crohn’s disease [86]. One disadvantage of the guided selection technique is that the construction of hybrid libraries can result in changes of the paratope altering the antibody fine specificity as observed previously [50, 87, 88]. This phenomenon was observed by using an “in series” process of guided selection technique for human interferon γ receptor 1 (IFNGR-1) [89]. To obtain a human antibody with the same paratope of the original rodent antibody, a variation of this technique was performed by the preservation of the CDR3 sequence of the heavy chain from the non-human template sequence [90, 91].

2.1.6. Advantages of phage display technology

Antibody phage display technology is more utilized in the discovery of therapeutic mAbs than any other display technologies due to many advantages: (1) it was the first display technology developed so the methodology is well-established; (2) it uses the low cost E. coli expression system; (3) it is possible to construct large naïve libraries for selection of human antibodies against most antigens and desired epitopes; (4) selection process is versatile with the ability to determine the epitope of the antibody; (5) it can be used for affinity maturation of antibodies; and (6) antibody humanization by guided selection technique to obtain human antibodies is possible [25, 92]. As disadvantages, it can be mentioned: (1) selection of an antibody with low affinity from naïve and synthetic libraries that implies that in vitro affinity maturation for therapeutic application is recommendable; and (2) low antibody expression in E. coli for some isolated antibody sequences.

2.2. Yeast display

The yeast display technology uses yeast cells to present exogenous peptides or antibody fragments on the cell surface. In this technology, exogenous molecules are fused to the a-agglutinin adhesion receptor of Saccharomyces cerevisiae which is localized on the yeast surface and the cell repertoire can be screened by flow cytometry [93]. A-agglutinin receptor acts as adhesion molecule that stabilizes cell-cell interactions and promotes fusion between an “a” and α haploid cell to obtain a diploid cell. This receptor is composed of the Aga1 and Aga2 protein. Aga1 protein is secreted and binds covalently to b-glucan present in the extracellular matrix of the yeast cell wall. Aga2 protein binds to Aga1 protein through two disulfide bonds and the antibody fragment is fused to the C-terminal end of Aga2 protein (Figure 3) [94]. Aga1 protein and the fusion protein are expressed by induction of the GAL1 promoter with galactose [95]. ScFv is the most frequent antibody format displayed on yeast surface. Other formats include Fab fragment, whole IgG and single domain antibodies [38, 96].

The library is constructed by cloning the antibody genes into the yeast display vector and has smaller size than phage display libraries. After yeast transformation and growth, antibody expression is induced and then flow cytometry screening is performed with specific ligands to enrich binders of the library. After about three rounds of antibody selection, the enriched library is transformed in E. coli for analysis of plasmid DNA by sequencing [96].

Yeast display technology is used to improve the ligand affinity of scFv fragments and thermal stability of proteins [97, 98, 99] and also to isolate novel antibodies with suitable affinity and specificity [94]. One advantage of this technology is the characterization of binding properties such as affinity of one clone displaying an antibody fragment on the yeast surface without sub-cloning, expression and purification steps [94]. The display level is diverse and the binding avidity is reduced due to the cell sorting potential of flow cytometry. Yeast cells can be sorted according to the antibody binding range to the antigen and also by antibody expression range on the yeast surface through labeling the cell with fluorophore-conjugated antigen and with reagents to identify epitope of tags [94]. Boder’s group used kinetic screening for a yeast display library containing random mutations and they isolated scFv clones with high affinity (48 fM) [100]. A naïve human scFv library composed by more than 10⁹ clones was constructed by yeast display technology; antibody clones were firstly selected by magnetic bead screening followed by flow cytometry screening, isolating antibodies with an affinity of nM range [101]. Magnetic bead screening was applied to remove yeast cells not presenting antibody fragments like the biopanning process used in the phage display technology. As a consequence, the yeast display library size became suitable for the antibody selection by flow cytometry [96].

The construction of a yeast display vector displaying a Fab fragment was reported [102] and a single vector presenting two expression cassettes with the GAL1 promoter was used. The heavy chain fragment was expressed as a fusion protein to the N-terminal end of Aga2 protein and the light chain gene was expressed as a soluble fragment, resulting in a Fab fragment assembled on the yeast surface. The affinity matured library allowed the selection of high affinity antibodies.

A novel approach combining phage and yeast display technologies was tested to select Fab fragments against antigen 85 of Mycobacterium tuberculosis [103]. Initially, a large naïve scFv library was selected by antigen binding using phage display technology. The enriched library with compatible size to flow cytometry screening was cloned into yeast display vector and highly specific antibodies were obtained. This strategy could be applied to any antigen and will serve as an alternative approach to isolate high affinity antibodies.

The major advantage of yeast display technology is the library screening using flow cytometry that allows defining specific parameters to select antibodies displayed on yeast surface. Yeast displaying antibodies can be sorted by binding to fluorescently-conjugated antigen and it is possible to separate clones quantitatively using binding affinity or dissociation kinetics parameters. Yeast cells can display about 10⁵ antibodies and the expression range can be evaluated also by binding of epitope tags using fluorophore-labeled reagents [104].

Another advantage is that this platform uses yeast and therefore presents post-translational modifications like existing in the mammalian system but not present in bacteria. Post-translational modifications include glycosylation of antibodies, appropriate protein folding in the endoplasmic reticulum in the presence of chaperones and improved solubility of the product [96, 104].

In comparison to phage display technology, a yeast display platform has a limitation of the library size, due to lower efficiency of yeast transformation [96, 104]. Efforts to circumvent this problem led to the improvement of yeast transformation efficiency, allowing the construction of libraries with 10¹⁰ clones [105]. Another disadvantage of this platform is the multivalent display of antibodies on yeast surface and the selection based on avidity parameters [96, 104].

Among cell surface display-based technologies, we mentioned yeast and mammalian display technologies in this chapter. A prokaryotic system such as bacterial cell surface display (either Gram-negative or Gram-positive bacteria) has also been developed with the selection of high affinity binders [106, 107, 108]. The library screening is performed through the binding of the protein displayed on the cell surface to a specific fluorescently labeled ligand and analyzed mainly by flow cytometry as occurs in other cell surface display technologies. An E. coli display system was first extensively studied for antibody fragment isolation, then variations of this methodology were developed by genetic engineering [108, 109, 110], and full-length IgG was also displayed on bacteria [111]. There are few works considering Gram-positive bacterial cell surface display. A Gram-positive Staphylococcus display system was investigated [108, 112] and high affinity small proteins known as affibody molecules were selected using this system [113, 114], opening an attractive perspective for future development.

3. Approved therapeutic monoclonal antibodies

By the end of 2016, 20 fully human mAbs were approved for therapeutic use by the US Food and Drug Administration (FDA) and often approved by the European Medicines Agency (EMA) too. The approved fully human mAbs are derived basically from two technologies: phage display or transgenic mice expressing human antibody genes [132, 133]. Among approved mAbs, five were generated by phage display with selection of antigen-specific binders from two different libraries, Cambridge Antibody Technology - CAT (MedImmune, subsidiary of AstraZeneca) based on scFv fragments or Dyax Corp’s human Fab fragment libraries [25, 134]. The other 15 mAbs were developed in transgenic mice, with integrated human immunoglobulin loci.

Considering the therapeutic mAbs approved which used phage display technology to acquire the human antibody composition, there are examples of different targets for immune intervention: two (adalimumab and belimumab) are in use for autoimmune diseases, one (raxibacumab) is for control of Bacillus anthracis infection and two others (ramucirumab and necitumumab) address growth factor receptors for cancer treatment.

The first fully human mAb approved for therapy in 2002 (FDA) and 2003 (EMA)—adalimumab (Humira^®, AbbVie Inc., formerly Abbott Laboratories)—was generated by phage display technology [25, 134]. Adalimumab is an anti-TNFα mAb developed in 1993 through a collaboration between BASF Bioresearch Corporation and CAT using an anti-TNF murine antibody (MAK195) from BASF as a template for guided selection of human antibody V-domains with CAT’s antibody phage display technology [25]. Adalimumab was first approved for treatment of rheumatoid arthritis (RA) under the brand name Humira (human monoclonal antibody in rheumatoid arthritis) [25, 135]. Besides RA, adalimumab is currently used in the treatment of plaque psoriasis, ulcerative colitis, Crohn’s disease, non-infectious uveitis, hidradenitis suppurativa, psoriatic arthritis, juvenile idiopathic arthritis and ankylosing spondylitis [136].

Nine years after the approval of the first human mAb developed by phage display technology (adalimumab), in 2011 belimumab (Benlysta, GSK) was approved for the treatment of systemic lupus erythematosus [25, 134, 137]. Belimumab was selected using CAT library as a result of the collaboration between CAT and Human Genome Sciences (now GlaxoSmithKline), and targets the soluble form of human B-lymphocyte stimulator (BLyS) [25, 134]. Under a license to use the CAT library, Human Genome Sciences (now GSK) discovered Raxibacumab (Abthrax) also using phage display. Raxibacumab binds the Bacillus anthracis protective antigen (PA) and was approved by FDA in 2012 for the prophylaxis and treatment of anthrax [25, 134, 138, 139].

In addition to the three previously described antibodies, which were discovered using scFv-fragment CAT library by antibody phage display, two mAbs—ramucirumab and necitumumab—were derived from the same technology but from a different library, a human Fab-fragment library constructed by de Haard and colleagues at Dyax [25, 134]. Ramucirumab (Cyramza, Eli Lilly) is an anti-VEGFR-2 (vascular endothelial growth factor receptor 2) mAb approved for the treatment of cancer (gastric or gastroesophageal junction, non-small cell lung and colorectal) in 2014 [140]. Necitumumab (Portrazza, Eli Lilly) targets epidermal growth factor receptor (EGFR) and blocks binding to epidermal growth factor (EGF) [25, 134]. This mAb gained first marketing approval for FDA and EMA in 2015 and 2016, respectively, for the treatment of non-small cell lung cancer [25, 141, 142].

Ranibizumab (Lucentis, Genentech), an anti-VEGF-A (vascular endothelial growth factor A) Fab fragment, was generated by the humanization of the murine mAb A4.6.1 [134]. Based on a random mutation library, clones were selected by phage display [143]. Afterward, an alanine scanning study and information of the crystal structure of the Fab-VEGF complex were used for affinity maturation [144, 145]. This mAb was approved in the US in 2006 for the treatment of age-related macular degeneration [25, 134], and posteriorly for the treatment of macular edema after retinal vein occlusion, diabetic macular edema and diabetic retinopathy [25].

4. Future perspectives of the development of recombinant antibodies

This chapter is focused on fully human therapeutic mAbs, mainly those derived from phage display technologies. Other technologies emerged in recent years for the obtainment of human mAbs with high promises of success, derived directly from human B lymphocytes by two main approaches, immortalization of memory B cells by polyclonal stimulation followed by EBV transformation and/or the capture and sorting of memory B cells or plasmablasts followed by amplification of the mAb variable chains expressed by the single B cell, which can be transfected to mammalian cells [27]. The natural pairing of rearranged heavy chain and light chains regions can be found only in B cells. Display technologies add complexity to the repertoire by pairing light and heavy chains by chance. A very promising new class of antibodies consists of single domain antibodies from camels and sharks comprising only one variable domain of the heavy chain [146, 147]. These molecules are stable, non-aggregating molecules both in vitro and in vivo. Carrying the ability to bind antigens intracellularly as intrabodies inside the nucleus or cytosol makes them an important platform for antigen trafficking and knockdown, meaning a promise for the future [38].

It draws attention when analyzing the therapeutic mAbs in the market that the majority of them target cancer and autoimmune diseases, while some are directed to other conditions and very few are directed to infectious diseases treatment. It is also more astonishing since the first use of antibodies in immunotherapy fought against infectious diseases by the end of the nineteenth century. One obvious reason is that bacterial infections can be treated with antibiotics and many can be prevented by vaccination. Viral infections, on the other hand, are more complicated to treat by vaccination or treatment with antibodies as some viruses exhibit high mutation rates.

Broadly neutralizing mAbs to influenza viruses can be used to probe in vitro vaccine candidates and provide useful information for understanding data generated by preliminary in vivo studies, contributing to a universal influenza virus vaccine strategy [148, 149]. The identification of new conserved epitopes resulted from analysis with two broadly neutralizing mAbs, specific for the HA2 subunit of influenza virus belonging to different clades. Both mAbs were generated by phage display from B cells of an influenza vaccinated individual [150] and from a “non-immune” human antibody library [151]. Contrary to the disadvantages listed for phage display libraries, these are high affinity mAbs, in the range of nanomolar and picomolar, respectively.

Generation of mAbs by phage display technology was a breakthrough since this technology opened possibilities to isolate human antibodies for any kind of epitope/antigen without immunization. The success of this technology can be observed by the approval of some drugs, mAbs and other kinds of proteins, and many more are under clinical studies at different stages. There are some candidates for Phase 3 clinical trial, bringing promises of new drugs in the near future [25, 134]. As a perspective for infectious diseases, this technology should be more widely applied for rapid screening of antibodies for diagnostic or therapeutic purposes based on immune or naïve human libraries when epidemic infectious disease breaks without an available drug for its treatment. Other perspective concerns the combinatorial library construction. Recently, the human antibody repertoire derived from blood of human naïve or immunized donors has been intensively analyzed by next-generation sequencing [152, 153]. Advances in the knowledge of the human antibody repertoire would help in the designing of antibody libraries and for antibody maturation of existing human libraries, making possible the selection of mAbs with higher affinity for clinical use.